"Interferon-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
| Descriptor ID |
D016898
|
| MeSH Number(s) |
D12.644.276.374.440.890.250 D12.776.467.374.440.890.250 D23.529.374.440.890.250
|
| Concept/Terms |
Interferon-alpha- Interferon-alpha
- Interferon alpha
- alpha-Interferon
- alpha Interferon
- Interferon, Lymphoblastoid
- Lymphoblastoid Interferon
- Interferon, Lymphoblast
- Lymphoblast Interferon
- Interferon Alfa
- Interferon, alpha
- Interferon, Leukocyte
- Leukocyte Interferon
Interferon alpha-17- Interferon alpha-17
- Interferon alpha 17
- Interferon alpha-T
- Interferon alpha T
- LeIF I
- Interferon alpha-88
- Interferon alpha 88
Interferon alpha-7- Interferon alpha-7
- Interferon alpha 7
- LeIF J
- Interferon alpha-J
- Interferon alpha J
Interferon alpha-5- Interferon alpha-5
- Interferon alpha 5
- Interferon alpha5
- IFN-alpha5
- IFN alpha5
Interferon alpha-2- Interferon alpha-2
- Interferon alpha 2
- Interferon-alpha 2
- Interferon alpha-A
- Interferon alpha A
- LeIF A
- IFN-alpha 2
- IFN-alpha-2
|
Below are MeSH descriptors whose meaning is more general than "Interferon-alpha".
Below are MeSH descriptors whose meaning is more specific than "Interferon-alpha".
This graph shows the total number of publications written about "Interferon-alpha" by people in this website by year, and whether "Interferon-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1997 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 3 | 1 | 4 |
| 2004 | 2 | 2 | 4 |
| 2005 | 2 | 3 | 5 |
| 2006 | 3 | 7 | 10 |
| 2007 | 4 | 0 | 4 |
| 2008 | 4 | 3 | 7 |
| 2009 | 4 | 1 | 5 |
| 2010 | 4 | 4 | 8 |
| 2011 | 1 | 0 | 1 |
| 2012 | 6 | 1 | 7 |
| 2013 | 7 | 1 | 8 |
| 2014 | 4 | 3 | 7 |
| 2015 | 0 | 3 | 3 |
| 2016 | 1 | 3 | 4 |
| 2017 | 40 | 32 | 72 |
| 2018 | 26 | 20 | 46 |
| 2019 | 9 | 10 | 19 |
| 2020 | 5 | 8 | 13 |
| 2021 | 10 | 9 | 19 |
To return to the timeline, click here.
Below are the most recent publications written about "Interferon-alpha" by people in Profiles.
-
Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. Ann Med. 2021 12; 53(1):391-401.
-
Update on human genetic susceptibility to COVID-19: susceptibility to virus and response. Hum Genomics. 2021 08 25; 15(1):57.
-
Efficacy and safety of pegylated interferon-a2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study. Int J Infect Dis. 2021 Oct; 111:281-287.
-
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021 08 19; 6(62).
-
CD169 Defines Activated CD14+ Monocytes With Enhanced CD8+ T Cell Activation Capacity. Front Immunol. 2021; 12:697840.
-
BCG vaccination induces enhanced frequencies of dendritic cells and altered plasma levels of type I and type III interferons in elderly individuals. Int J Infect Dis. 2021 Sep; 110:98-104.
-
Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. Cell Mol Immunol. 2021 09; 18(9):2128-2139.
-
Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. J Clin Invest. 2021 07 15; 131(14).
-
Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study. Virol J. 2021 07 08; 18(1):142.
-
Current Understanding of Multisystem Inflammatory Syndrome (MIS-C) Following COVID-19 and Its Distinction from Kawasaki Disease. Curr Rheumatol Rep. 2021 07 03; 23(8):58.